Shilpa Medicare arm inks pact with Dr Reddy’s to manufacture Sputnik V vaccine

By: |
May 17, 2021 11:46 AM

"The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing.

sputnik v vaccineThe vaccine is priced at Rs 948, with five per cent GST per dose (retail price of Rs 995.40). (File photo: Reuters)

Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy’s Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V.

“The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy’s Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka,” Shilpa Medicare said in a regulatory filing.

The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy’s will facilitate the transfer of the sputnik technology to SBPL.

Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy’s is responsible for distribution/marketing of the vaccine in its marketing territories.

Shilpa Medicare said the companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future.

Reddy’s Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Deepak Sapra, a senior executive of the drug-maker, taking the first shot.

The vaccine is priced at Rs 948, with five per cent GST per dose (retail price of Rs 995.40).

The first consignment of imported doses of the Sputnik V vaccine from Russian Direct Investment Fund (RDIF) landed in India on May 1, and received regulatory clearance from the Central Drugs Laboratory.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Kirloskar Brothers sets up new manufacturing division for products used for nuclear applications
2Twitter failed to comply with IT rules, deliberately chose path of non-compliance: Ravi Shankar Prasad
3Sequoia, Elevation Capital, Y Combinator, others put $38 million in fintech startup FamPay